CHINARES PHARMA (03320) has released the unaudited preliminary financial data for Tasly Pharmaceutical Group Co.,Ltd. for the year ended December 31, 2025. Tasly Pharmaceutical achieved total operating revenue of 8.236 billion yuan, representing a decrease of 3.08% compared to the previous year. The net profit attributable to shareholders of the listed company was 1.105 billion yuan, indicating a year-on-year increase of 15.68%. In terms of the changes, the primary reason for the decline in operating revenue was a 14.24% year-on-year reduction in pharmaceutical commercial revenue, primarily from its chain pharmacy business, which was affected by industry-wide policies such as "outpatient统筹" (outpatient coordinated billing).